Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

49.47USD
1:30am IST
Change (% chg)

$-0.80 (-1.59%)
Prev Close
$50.27
Open
$50.06
Day's High
$50.56
Day's Low
$49.30
Volume
1,407,677
Avg. Vol
1,118,557
52-wk High
$66.55
52-wk Low
$48.01

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $51,658.52
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 2.71

Financials

  TEVA.N Industry Sector
P/E (TTM): 33.57 36.26 36.23
EPS (TTM): 1.50 -- --
ROI: 4.12 14.29 13.79
ROE: 5.06 15.13 14.74

BRIEF-Teva announces data from second phase 3 study of SD-809

* Teva announces positive top-line data from second phase 3 study of SD-809 in Tardive Dyskinesia (TD)

22 Sep 2016

MEDIA-Bayer's dermatology unit sale said to attract Teva and Perrigo - Bloomberg

-- Note: Reuters has not verified this story and does not vouch for its accuracy

20 Sep 2016

BRIEF-Teva and regeneron announce global collaboration to develop Fasinumab

* To pay Regeneron $250 million upfront, share equally in global commercial value, ongoing research & development costs of about $1 billion

20 Sep 2016

BRIEF-Regeneron, Teva collaborate to develop, commercialize Fasinumab

* Regeneron and Teva announce global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain

20 Sep 2016

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

20 Sep 2016

BRIEF-Teva announces results from exploratory 52-week phase 2 PRIDE-HD study of Pridopidine in Huntington disease

* Announces results from exploratory 52-week phase 2 PRIDE-HD study of pridopidine in Huntington disease

19 Sep 2016

BRIEF-Teva launches authorized generic of Cubicin in the U.S.

* Teva strengthens injectables portfolio with the launch of an authorized generic of Cubicin (Daptomycin for injection) in the United States Source text for Eikon: Further company coverage:

15 Sep 2016

Teva Pharm, Intel to study Huntington disease progression

JERUSALEM, Sept 15 Teva Pharmaceutical Industries is collaborating with Intel Corp to develop a wearable device and machine learning platform for Huntington disease patients, Teva said on Thursday.

15 Sep 2016

BRIEF-Teva collaborates with Intel to develop a device for use in huntington disease

Sept 15 Teva Pharmaceutical Ltd Says It Will Deploy The Technology Platform In A Sub

15 Sep 2016

Teva says aims to launch EpiPen-like device by 2018 in U.S.

Teva Pharmaceutical Industries Ltd said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device for treating severe allergic reactions, a move that would challenge the branded product's overwhelming market dominance.

10 Sep 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF78.10 +0.10
Biogen Inc (BIIB.OQ) $314.53 +4.71

Earnings vs. Estimates